Title:Pregnancy Complicated by the Most Frequent Forms of Maturity Onset Diabetes of the Young: A Narrative Review on Its Pharmacological Implications
Volume: 16
Issue: 3
Author(s): Claudio Daniel Gonzalez, Victoria Insussarry Perkins, Agustina Alves de Lima, Rocio Fogar, Gustavo D. Frechtel and Guillermo Di Girolamo*
Affiliation:
- Universidad de Buenos Aires, Facultad de Medicina, Centro de Vigilancia y Seguridad de Medicamentos, Buenos Aires,Argentina
Keywords:
Monogenic diabetes, MODY, anti-diabetic drugs, pregnancy, insulin, sulfonylureas.
Abstract:
Background: Monogenic Diabetes (MFD) represents close to 2% of all the cases of diabetes
diagnosed in people younger than 45 years old. Maturity-Onset Diabetes of the Young
(MODY), neonatal diabetes, and several syndromic forms of diabetes are included among the most
accounts for about typical forms of MDF. MODY is the most frequent type of MFD, with MODY
1, 2, 3, and 5 being the most prevalent forms. The aim of this narrative review is to describe pregnancy
associated changes in the pharmacological profile of the antidiabetic drugs used in women
with the most frequent MODY subtypes.
Methods: A comprehensive literature search was carried out to identify eligible studies from MEDLINE/
PubMed, EMBASE, and SCIELO databases from 1970 to 2019 first semester.
Results: Pregnancy introduces changes in the pharmacodynamic and pharmacokinetic profile of
some of the treatments used in MODY. MODY 3 (also known as HNF1-A MODY) is the most frequent
MDF. MODY 3 patients are highly sensitive to Sulfonylureas (SU). This is also the case for
MODY pregnant women. This high sensitivity to SU is also registered in patients with MODY 1
(HNF4-A MODY). Pharmacodynamic changes have been proposed to explain this behavior (Epac2
hyperactivity). However, changes in expression/activity of the metabolizing CYP2C9 cytochrome
and/or alterations in the drug transporters oatp1 (Slc21a1), Lst-1 (Slc21a6), OATPD (SLC21A11),
and oat2 may better explain, at least in part, this phenomenon by an increase in the concentration
of the active drug.
Conclusion: The impact of changes in the pharmacological behavior of drugs like SU and other
metabolized/transported by mechanisms altered in a pregnancy complicated by MODY is unknown.
However, switching-to-insulin recommendation formulated for MODY 1 and 3 seems to
be justified. Further research in this field is needed for a better understanding of changes in drug activity
associated with this particular subset of patients with MFD.
